LifeMD, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 14, 2020 and accepted by EDGAR at Aug 14, 2020, 17:05 ET.
Management's discussion and analysis
As filed, 42,481 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q includes a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) that reflect management’s current views with respect to future events and financial performance. These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Our financial statements are prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report. The forward-looking statements made in this report are based only on events or information as of the date on which the statements are made in this report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this report and the documents we refer to in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. These risks include, by way of example and without limitation:
- our ability to successfully commercialize our products on a large enough scale to generate profitable operations;
- our ability to maintain and develop relationships with customers and suppliers;
- our ability to successfully integrate acquired businesses or new brands;
- the impact of competitive products and pricing;
- supply constraints or difficulties;
- general economic and business conditions;
- business interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks (such as COVID-19);
- our ability to continue as a going concern;
- our need to raise additional funds in the future;
- our ability to successfully recruit and retain qualified personnel;
- our ability to successfully implement our business plan;
- our ability to successfully acquire, develop or commercialize new products and equipment;
- intellectual property claims brought by third parties; and
- the impact of any industry regulation.
21
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission (“SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.
As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms “Company,” “we,” “us,” and “our” refer to Conversion Labs, Inc. (formerly known as Immudyne, Inc.), our wholly owned subsidiary Conversion Labs PR, LLC (formerly Immudyne PR LLC, now “Conversion Labs PR”), a Puerto Rico limited liability company (“Conversion Labs PR”) and our majority-owned subsidiaries LegalSimpli Software, LLC, a Puerto Rico limited liability company (“LegalSimpli”). Unless otherwise specified, all dollar amounts are expressed in United States dollars.
Corporate History
Conversion Labs, Inc., was formed in the State of Delaware on May 24, 1994, under our prior name, Immudyne, Inc. We changed our name to Conversion Labs, Inc. on June 22, 2018. Further, in connection with changing its name, the Company changed its trading symbol to CVLB. On April 1, 2016, our majority-owned subsidiary, Immudyne PR LLC (“Immudyne PR”), which was initially formed for the purpose of a joint venture with the original owners of one of our skincare products, amended and restated its operating agreement whereby we increased our ownership and voting interest in Immudyne PR to 78.2%. Concurrent with the name change of the parent company to Conversion Labs, Inc. completed in 2018, Immudyne PR was renamed to Conversion Labs PR LLC (now known as “Conversion Labs PR”). On April 25, 2019, the operating agreement of Conversion Labs PR was amended and restated in its entirety after acquiring the remaining minority interest in the Conversion Labs PR, which is now a wholly-owned subsidiary of the Company.
In June 2018, Conversion Labs closed the strategic acquisition of 51% of LegalSimpli Software, LLC (“LegalSimpli”), a software as a service (SaaS) for converting, editing, signing and sharing PDF documents. In addition to LegalSimpli’s growth business model, this acquisition added deep search engine optimization and search engine marketing expertise to the Company.
In early 2019, we also launched a service-based business under the name Conversion Labs Media LLC, which was to be used to run e-commerce marketing campaigns for other online businesses. However, this business was discontinued in 2019 in order to focus on our core business as well the expansion of our telehealth opportunities.
In June 2019, a joint venture with GoGoMeds.com was formed allowing us to market branded and generic prescription drugs that are then sold and shipped (via GoGoMeds) online directly to consumers in all 50 states and the District of Columbia.
Business Overview
The Company is a direct response healthcare company that provides a convenient, cost-effective and smarter way for consumers to access high quality Over The Counter (OTC) products and prescription medications. The U.S. healthcare system is undergoing a paradigm shift largely due to new technologies and the emergence of direct-to-consumer healthcare. We believe the traditional model of visiting a doctor’s office, receiving a physical prescription, visiting a neighborhood pharmacy, and returning to see a doctor for follow up care or prescription refills is inefficient, costly to patients, and discourages many patients from seeking much needed medical care. Direct-to-consumer telemedicine companies, like our Company, offer patients immediate and virtual treatment from licensed physicians, and the home delivery of prescription medications, devices and diagnostics bundled with over-the counter wellness products.
We have built a platform that allows us to efficiently launch telehealth and wellness product lines wherever we determine there is a market need. Our platform is supported by a driven team of digital marketing and branding experts, data analysts, designers, and engineers focused on building enduring brands.
Telemedicine Platform
Beginning in 2019, we have made significant investments in our telemedicine technology platform which is the backbone of our physician network, pharmacy provider, CRM system, and third-party advertising platforms. This platform facilitates patient consultations, virtual prescriptions, fulfillment, and follow-up consultations.
Our Telehealth Brands
Our telehealth brands have been built with one singular focus in mind: to become the leading provider of quality healthcare in a virtual setting. To this end, we work with our physicians, our advisors, and our patients to ensure that we can provide the ultimate quality of care. We believe the long-term success of our telehealth business will be driven primarily by the outstanding care we provide in our services and product offerings. Our current brand portfolio is comprised of telehealth brands respectively targeting three market segments: hair loss, men’s health, and emergency medications.
Majority Owned Subsidiary: PDFSimpli
PDFSimpli is a PDF conversion software product, which was acquired through the purchase of 51% of the membership interests of LegalSimpli a Puerto Rico limited liability company, which operates a marketing-driven software solutions business. PDFSimpli enables users to convert, edit and sign PDF documents. As of March 1, 2020, PDFSimpli was ranked in the top 5,750 websites globally, in which it was also ranked in the top 1,200 for specific countries with more than 4.5 million registrants globally. Since its launch, PDFSimpli has converted or edited over 5 terabytes of documents for customers from the legal, financial, real-estate and academic sectors. PDFSimpli has over 39,000 active subscriptions as of March 1, 2020.
Impact of COVID-19 Pandemic
We are closely monitoring how the spread of the COVID-19 pandemic caused by the novel coronavirus is affecting our employees, customers and business operations. We have developed preparedness plans to help safeguard the safety of our employees and customers, while safely continuing business operations.
Due to the global spread of the outbreak, the severity of the pandemic in New York, California, and Puerto Rico where we have corporate offices, and in line with guidance from public health officials, we have temporarily restricted access to our offices and implemented a mandatory remote work policy during this period. Our offices will remain closed until we are able to safely and responsibly re-open them in accordance with governmental and public health guidance, as well as health and safety policies tailored to our operations.
As a result of the early measures we took in response to the COVID-19 pandemic to protect our employees and business operations, our business has not been materially negatively impacted during these extraordinary times. We have experienced relatively minor impacts on our inventory availability and delivery capacity since the outbreak, none of which has materially impacted our ability to service our customers. We have taken measures to bolster key aspects of our supply chain to support our continued growth. We continue to work with our existing manufacturing, logistics and other supply chain partners to build key processes to ensure our ability to service our customers.
We are also carefully monitoring shifting consumer behavior from brick and mortar retail and physical healthcare offices to our online platform. We have observed continued strength in our e-commerce sales since the end of the quarter ended June 30, 2020, due in part to changing consumer behavior during the COVID-19 pandemic and widespread awareness and acceptance of telemedicine. Telemedicine businesses, such as ours, have benefitted from increased coverage and visibility due to quarantine measures and policies adopted widely across the country. We believe the increased awareness of telehealth is reflected in the rapid growth we are seeing across our telehealth brands.
Results of Operations
Comparison of the Three Months Ended June 30, 2020 to the Three Months Ended June 30, 2019
Revenue
Our financial results for the three months ended June 30, 2020 are summarized as follows in comparison to the three months ended June 30,2019:
| June 30, 2020 $% of Sales | June 30, 2019 $% of Sales | |||
|---|---|---|---|---|
| Product revenues, net | 7,869,813 | 87% | 2,307,909 | 86% |
| Software revenues, net | 1,219,970 | 13% | 390,498 | 14% |
| Service revenues, net | - | 0% | - | 0% |
| Total revenues, net | $9,089,783 | 100% | $2,698,407 | 100% |
| Cost of product revenue | 2,118,001 | 23% | 589,690 | 22% |
| Cost of software revenue | 72,207 | 1% | 65,521 | 2% |
| Total cost of revenue | 2,190,208 | 24% | 655,211 | 24% |
| Gross profit | $6,899,575 | 76% | $2,043,196 | 76% |
| Selling & marketing expenses | 8,394,331 | 92% | 2,215,913 | 82% |
| General and administrative expenses | 1,338,549 | 15% | 372,853 | 14% |
| Operating expenses | 203,260 | 2% | 95,477 | 4% |
| Customer service expenses | 89,482 | 1% | 141,278 | 5% |
| Development costs | 92,325 | 1% | 50,838 | 2% |
| Total expenses | $10,117,947 | 111% | $2,876,360 | 107% |
| Loss from operations | $(3,218,372) | (35)% | $(833,164) | (31)% |
| Other income (expenses) | (228,875) | (30)% | (129,826) | (5)% |
| Income from continuing operations before provision for income taxes | $(3,447,247) | (38)% | $(962,990) | (36)% |
| Income taxes | - | 0% | - | 0% |
| Net income (loss) attributable to noncontrolling interests | $(68,131) | (1)% | $(144,887) | (5)% |
| Net income (loss) attributable to Conversion Labs, Inc. | $(3,379,116) | (37)% | $(818,103) | (30)% |
Revenues for the three months ended June 30, 2020 were approximately $9.1 million, an increase of 236.9% compared to approximately $2.3 million for the three months ended June 30, 2019. The increase in revenues was attributable to both the increase in product revenue of 241.0% and an increase in software revenue of 212.4%. Product revenue accounts for 87% of total revenue and has increased in the three months ended June 30, 2020 due to an increase in online sales demands. Management attributes a portion of this increased demand to the nationwide lockdown resulting from COVID-19 precautions and the resulting increase in consumers’ purchases online. Software revenue accounts for 13% of total revenue and has steadily increased quarter over quarter due to a combination of higher demand, market awareness, and continued marketing campaigns.
Cost of product revenues consists primarily of product material costs and fulfillment costs directly attributable to the production of our products. Cost of software revenue consist primarily of credit card processing fees and information technology fees related to our online platform. Total cost of revenue increased by approximately 234.3.% to approximately $2.2 million for the three months ended June 30, 2020 compared to approximately $655,000 for the three months ended June 30, 2019. The increase in cost of revenues was due to increased revenues and related increase in merchant and other processing fees incurred due to the higher sales volumes in both our product and software sales.
Gross profit increased by approximately 237.7% to approximately $6.9 million for the three months ended June 30, 2020 compared to approximately $2.0 million for the three months ended June 30, 2019. This is a result of the increased sales. Gross profit as a percentage of revenues remained consistent at 76% for the three months ended June 30, 2020 and for the three months ended June 30, 2019.
Operating Expenses
| Three Months Ended June 30, 2020 | 2019 | |
|---|---|---|
| Selling & marketing expenses | $8,394,331 | $2,215,913 |
| General and administrative expenses | 1,338,549 | 372,853 |
| Operating expenses | 203,260 | 95,477 |
| Customer service expenses | 89,482 | 141,278 |
| Development costs | 92,325 | 50,838 |
| Total operating expenses | $10,117,947 | $2,876,360 |
Operating expenses for the three months ended June 30, 2020 were approximately $10.1 million, as compared to approximately $2.9 million for the three months ended June 30, 2019. This represents an increase of 251.8%, or $7.2 million. The increase is primarily attributable to:
(i) Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the three months ended June 30, 2020, the Company had an increase of approximately $5.1 million in selling and marketing costs resulting from additional sales and marketing initiatives to drive further growth throughout all of 2020.
(ii) General and administrative expenses: This mainly consists of payroll expenses for executive management, stock-based compensation, amortization expense and legal and professional fees. During the three months ended June 30, 2020, the Company has had an increase of approximately $950,000 in general and administrative expenses, primarily related to stock-based compensations and infrastructure to support the increase in sales volume.
(iii) Other operating expenses: This mainly consists of rent, insurance, royalty expense, bank charges and IT services for our online products. During the three months ended June 30, 2020, the Company had an increase of approximately $100,000, primarily related to increases in sales volume driving up bank charges, IT services, and offices supplies offset by decreases in rent and royalty expense.
(iv) Customer service expenses: This consists of payroll and benefit expenses related to the Company’s customer service department located in Puerto Rico. During the three months ended June 30, 2020, the Company had a decrease of approximately $51,000, primarily related to decreases in headcount in the Company’s customer service department.
(v) Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the three months ended June 30, 2020, the Company had an increase of approximately $41,000, primarily resulting from technology platform improvements for LegalSimpli and amortization expenses at Conversion Labs PR.
25
Other Expense
| Three Months Ended June 30, 2020 | 2019 | |
|---|---|---|
| Interest expense | $228,875 | $129,826 |
| Total | $228,875 | $129,826 |
Other expense for the three months ended June 30, 2020 increased by $99,000 compared to the three months ended June 30,2019. The increase in other expense is primarily attributable to an increase in the amortization of debt discount.
Comparison of the Six Months Ended June 30, 2020 to the Six Months Ended June 30, 2019
Revenue
Our financial results for the six months ended June 30, 2020 are summarized as follows in comparison to the six months ended June 30, 2019:
| June 30, 2020 $% of Sales | June 30, 2019 $% of Sales | |||
|---|---|---|---|---|
| Product revenues, net | 10,825,614 | 81% | 4,729,435 | 88% |
| Software revenues, net | 2,568,981 | 19% | 667,962 | 12% |
| Service revenues, net | - | 0% | - | 0% |
| Total revenues, net | $13,394,595 | 100% | $5,397,397 | 100% |
| Cost of product revenue | 3,462,161 | 26% | 1,199,866 | 22% |
| Cost of software revenue | 487,686 | 4% | 133,318 | 2% |
| Total cost of revenue | 3,949,847 | 29% | 1,333,184 | 25% |
| Gross profit | $9,444,748 | 71% | $4,064,213 | 75% |
| Selling & marketing expenses | 11,140,213 | 83% | 4,206,894 | 78% |
| General and administrative expenses | 2,507,527 | 19% | 707,859 | 13% |
| Operating expenses | 327,751 | 2% | 181,263 | 3% |
| Customer service expenses | 257,667 | 2% | 268,216 | 5% |
| Development costs | 170,467 | 1% | 96,515 | 2% |
| Total expenses | $14,403,625 | 108% | $5,460,747 | 101% |
| Loss from operations | $(4,958,877) | (46)% | $(1,396,534) | (30)% |
| Other income (expenses) | (1,021,914) | (9)% | (300,020) | (6)% |
| Income from continuing operations before provision for income taxes | $(5,980,791) | (55)% | $(1,696,554) | (36)% |
| Income taxes | - | 0% | - | 0% |
| Net income (loss) attributable to noncontrolling interests | $(206,947) | (2)% | $(214,702) | (5)% |
| Net income (loss) attributable to Conversion Labs, Inc. | $(5,773,844) | (53)% | $(1,481,852) | (31)% |
26
Revenues for the six months ended June 30, 2020 were approximately $13.4 million, an increase of 148.2% compared to approximately $5.4 million for the six months ended June 30, 2019. The increase in revenues was attributable to both the increase in product revenue of 128.9% and an increase in software revenue of 284.6%. Product revenue accounts for 81% of total revenue and has increased in the six months ended June 30, 2020 due to an increase in online sales demands. Management attributes a portion of this increased demand to the nationwide lockdown resulting from COVID-19 precautions and the resulting increase in consumers’ purchases online. Software revenue accounts for 19% of total revenue and has steadily increased quarter over quarter due to a combination of higher demand, market awareness, and continued marketing campaigns.
Cost of product revenues consists primarily of product material costs and fulfillment costs directly attributable to product production. Cost of software revenue consist primarily of credit card processing fees and information technology fees related to our online platform. Total cost of revenue increased by approximately 196.3% to approximately $3.9 million for the six months ended June 30, 2020 compared to approximately $1.3 million for the six months ended June 30,2019. The increase in cost of revenues was due to increased revenues and a related increase in merchant and other processing fees incurred due to the higher sales volumes in both our product and software sales.
Gross profit increased by approximately 132.4% to approximately $9.4 million for the six months ended June 30,2020 compared to approximately $4.1 million for the six months ended June 30, 2019. This is due to increased sales. Gross profit as a percentage of revenues was 71% for the six months ended June 30, 2020 versus 75% for the six months ended June 30, 2019. The decrease of 4% is attributed to the higher cost of sales incurred during the second quarter of 2020 resulting from the use of different suppliers. New suppliers were used to supplement production for increased product demand.
Operating Expenses
| Six Months Ended June 30, 2020 | 2019 | |
|---|---|---|
| Selling & marketing expenses | $11,140,213 | $4,206,894 |
| General and administrative expenses | 2,507,527 | 707,859 |
| Operating expenses | 327,751 | 181,263 |
| Customer service expenses | 257,667 | 268,216 |
| Development costs | 170,467 | 96,515 |
| Total operating expenses | $14,403,625 | $5,460,747 |
Operating expenses for the six months ended June 30, 2020 were approximately $14.4 million, as compared to approximately $5.5 million for the six months ended June 30, 2019. This represents an increase of 163.8%, or $8.9 million. The increase is primarily attributable to:
(i) Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the six months ended June 30,2020, the Company had an increase of approximately $7 million in selling and marketing costs. This resulted from additional sales and marketing initiatives to drive further growth throughout all of 2020.
(ii) General and administrative expenses: This mainly consists of payroll expenses for executive management, stock-based compensation, amortization expense and legal and professional fees. During the six months ended June 30, 2020, the Company has had an increase of approximately $1.8 millions in general and administrative expenses mainly related to stock-based compensations and infrastructure to support the increase in sales volume.
27
(iii) Other operating expenses: This consists of rent, insurance, royalty expense, bank charges and IT services for our online products. During the six months ended June 30, 2020, the Company had an increase of approximately $146,000, primarily related to increases in sales volume driving up banking fees, IT services, and offices supplies, offset by decreases in rent and royalty expense.
(iv) Customer service expenses: This mainly consists of payroll and benefit expenses related to the Company’s customer service department located in Puerto Rico. During the six months ended June 30, 2020, the Company had a decrease of approximately $11,000, primarily related to decreases in headcount in the Company’s customer service department effected in the second quarter.
(v) Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the six months ended June 30, 2020, the Company had an increase of approximately $41,000, primarily resulting from technology platform improvements for LegalSimpli and amortization expenses at Conversion Labs PR.
| Six Months Ended June 30, 2020 | 2019 | |
|---|---|---|
| Interest expense | $1,021,914 | $300,020 |
| Total | $1,021,914 | $300,020 |
Other expense for the six months ended June 30, 2020 increased by $721,894 compared to the six months ended June 30,2019. The increase in other expense is primarily attributable to increases in interest and amortization of debt discount.
Working Capital
| June 30, 2020 | December 31, 2019 | |
|---|---|---|
| Current assets | $2,191,089 | $2,747,402 |
| Current liabilities | 7,164,014 | 3,975,442 |
| Working capital | $(4,972,925) | $(1,228,340) |
Current assets decreased by approximately $556,000 for the six months ended June 30,2020. This is primarily attributable to a decrease in cash and cash equivalents of $770,000 due to payments on convertible notes. This was offset by an increase in accounts receivable and other current assets of $214,000. Current liabilities increased by $3.2 million which was primarily attributable to an increase in accounts payable and accrued liabilities as a result of the Company extending payables and credit terms with vendors during the six months ended June 30, 2020.
Liquidity and Capital Resources
| Six Months Ended June 30, 2020 | June 30,2019 | |
|---|---|---|
| Net loss | $(5,980,791) | $(1,696,554) |
| Net cash provided by operating activities | (1,097,281) | 640,182 |
| Net cash (used in) investing activities | (677,161) | (500,000) |
| Net cash provided by (used in) financing activities | 1,003,969 | (55,168) |
| Net increase (decrease) in cash | $(770,143) | $85,014 |
Since inception, the Company has funded operations through the revenues of its products, issuance of common stock, receipt of loans and advances from officers and directors and the issuance of convertible notes to third-party investors.
Net cash provided by operating activities was approximately $1.1 million for the six months ended June 30, 2020, as compared with net cash used in operating activities of approximately $640,000 for the six months ended June 30, 2019.
Net cash used in investing activities for the six months ended June 30, 2020 was approximately $677,000, as compared with net cash provided by investing activities of $500,000 for the six months ended June 30, 2019. Net cash used in investing activities was primarily due to continued payments on the Company’s purchase of LegalSimpli of $400,000 and the cash paid for capitalized software costs of approximately $277,000.
Net cash provided by financing activities for the six months ended June 30, 2020 was $1,003,969, as compared with net cash used in financing activities of $55,168 for the six months ended June 30, 2019. During the six months ended June 30, 2020, financing activities consisted of proceeds from convertible notes payable $1,750,000, and cash receipts for shares of $1,889,000 which were offset by the repayment of notes payable of approximately $2,500,000, distributions of noncontrolling interests of $121,223 and payment for debt issuance costs of $15,000.
Liquidity and Capital Resources Outlook
The Company has funded operations in the past through the sales of its products, issuance of common stock and through loans and advances from officers and directors. The Company’s continued operations are dependent upon obtaining an increase in its sales volume and the continued financial support from officers and directors, obtaining funding from third-party sources or the issuance of additional shares of common stock.
The accompanying financial statements have been prepared on the basis that the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. As of June 30, 2020, the Company has an accumulated deficit approximating $23.7 million and has experienced significant losses from continuing operations. Based on the Company’s cash balance as of June 30, 2020, and projected cash needs, management estimates that it will need an additional $4.0 million through the next 12 months, either from increasing sales revenue and/or raising additional capital via the sale of common stock or other equity securities, or obtaining debt financing. Although management has been successful to date in raising necessary funding, there can be no assurance that sales revenue will substantially increase or that any required future financing can be successfully completed on a timely basis, or on terms acceptable to the Company. Based on these circumstances, management has determined that these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Critical Accounting Policies and Estimates
Our significant accounting policies are more fully described in the notes to our financial statements. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.
Revenue Recognition
The Company records revenue under the adoption of ASC 606 by analyzing exchanges with its customers using a five-step analysis:
1. Identify the contract
2. Identify performance obligations
3. Determine the transaction price
4. Allocate the transaction price
5. Recognize revenue
For the Company’s product-based contracts with customers, the Company has determined that there is one performance obligation and the delivery of this performance obligation is transferred at a point in time. The Company generally records sales of finished products once the customer places and pays for the order and the product is simultaneously shipped, but in limited cases if title does not pass until the product reaches the customer’s delivery site, then recognition of revenue should be deferred until that time, however the Company does not have a process to properly record the recognition of revenue if orders are not immediately shipped. Delivery is considered to have occurred when title and risk of loss have transferred to the customer, which is usually upon shipment of the product. The Company does sell a subscription based service which is based on the recurring shipment of products and billed as if the Company were receiving recurring revenues and orders each month, therefore, the Company records these upon shipment to the customer.
The Company records an estimate for provisions of discounts, returns, allowances, customer rebates and other adjustments for each shipment, and are netted with gross sales. The Company’s discounts and customer rebates are known at the time of sale and the Company appropriately debits net product revenues for these transactions based on the known discount and customer rebates. The Company estimates for customer returns and allowances based on estimates of historical transactions and accounts for such provisions during the same period in which the related revenues are earned. The Company has determined that the population of contracts with customers tends to be homogenous, so that review of the contracts and estimate of various revenue related adjustments can be applied to the entire portfolio population.
The Company offers a suite of software to customers as a monthly subscription-based service. This suite of software allows the user or subscriber to convert almost any type of document to other editable document type formats for easy editing. For these subscription-based contracts with customers, the Company offers a 14-day trial period which is billed at $1.95 for an initial period, a monthly subscription, or a yearly subscription to the Company’s software. The Company has estimated that there is one product and performance obligation that is delivered over time, as the Company allows the subscriber to access the service for the time period purchased. The Company allows the customer to cancel at any point during the billing cycle, in which case the customers subscription will not be renewed for the following month or year depending on the original subscription. The Company records the sales over the customers subscription period for monthly and yearly subscribers or at the end of the initial 14 day service period for customers who purchased the initial subscription. The Company offers a discount for purchase of the monthly and yearly subscriptions, which must be paid at the initiation of the contract term, so that the contract price is fixed at the contract initiation. Yearly and monthly subscriptions for the subscription are recorded net of the Company’s known discount. As of the period ended June 30, 2020 and as the year ended December 31, 2019, the Company has accrued contract liabilities of approximately $303,000 and $110,000, respectively which represent obligation on in-process monthly or yearly contracts with customers and yet to be recognized initial 14-day trial periods.
Customer discounts, returns and rebates on product revenues during the six months ended June 30, 2020 and six months ended June 30,2019 approximated $1.3 million and $713,000, respectively. Customer discounts and allowances on software revenues during the three months ended June 30, 2020 and the three months ended June 30, 2019 approximated $163,000 and $26,500, respectively.
Capitalized Software Costs
The Company capitalizes certain payroll and third-party costs related to internally developed software and amortize these costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell internally developed software. Certain development costs not meeting the criteria for capitalization, in accordance with ASC 350-40 Internal-Use Software, are expensed as incurred. As of June 30, 2020 and 2019, the Company capitalized $313,827 and $0 related to internally developed software costs which is included in development. As of June 30,2020, these costs include $40,000 in capitalized stock based compensation that was given to a third-party service provider. During the three months ending June 30, 2020 and 2019, the Company amortized $8,251 and $0 of capitalized software costs.
Intangible Assets
Intangible assets are comprised of customer relationship asset and purchased licenses with estimated useful lives of three years and indefinite lived, respectively. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset.
Income Taxes
The Company files corporate federal and state tax returns. Conversion Labs PR and LegalSimpli file tax returns in Puerto Rico, both are limited liability companies and file separate tax returns with any tax liabilities or benefits passing through to its members.
The Company records current and deferred taxes in accordance with Accounting Standards Codification (ASC) 740, “Accounting for Income Taxes.” This ASC requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses and determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The Company’s tax returns for all years since December 31, 2016, remain open to taxing authorities.
Stock-based Compensation
The Company follows the provisions of ASC 718, “Share-Based Payment”. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common stock shares using weekly price observations over an observation period that approximates the expected life of the options. The risk-free rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the estimated forfeiture rate included in the option valuation was zero.
Many of the assumptions require significant judgment and any changes could have a material impact in the determination of stock-based compensation expense.
Recently Issued Accounting Standards
In June 2018, the FASB issued ASU 2018-07, “Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” that expands the scope of ASC Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of ASC Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. We do not expect the implementation of this new pronouncement to have a material impact on our consolidated financial statements.
In July 2017, the FASB issued ASU No. 2017-11, “Earnings Per Share (Topic 260) and Derivatives and Hedging (Topic 815) - Accounting for Certain Financial Instruments with Down Round Features” (“ASU 2017-11”). Equity-linked instruments, such as warrants and convertible instruments may contain down round features that result in the strike price being reduced on the basis of the pricing of future equity offerings. Under ASU 2017-11, a down round feature will no longer require a freestanding equity-linked instrument (or embedded conversion option) to be classified as a liability that is remeasured at fair value through the income statement (i.e. marked-to-market). However, other features of the equity-linked instrument (or embedded conversion option) must still be evaluated to determine whether liability or equity classification is appropriate. Equity classified instruments are not marked-to-market. For earnings per share (“EPS”) reporting, the ASU requires companies to recognize the effect of the down round feature only when it is triggered by treating it as a dividend and as a reduction of income available to common shareholders in basic EPS. The amendments in this ASU are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. This standard was adopted on January 1, 2020 and did not have a material impact on the Company’s financial position, results of operations or cash flows.
Off-Balance Sheet Arrangements
We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.
Controls and procedures
As filed, 2,987 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based upon that evaluation and subject to the foregoing, our principal executive officer and principal financial officer concluded that, our disclosure controls and procedures were not effective due to the following material weakness(es) in internal control over financial reporting described below.
- Lack of a functioning audit committee and a lack of a majority of outside directors on the Company’s board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures;
- Inadequate segregation of duties consistent with control objectives;
- Insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both US GAAP and SEC Guidelines;
- Inadequate security and restricted access to computer systems including a disaster recovery plan;
- Lack of formal written policy for the approval, identification and authorization of related party transactions; and
- No written whistleblower policy.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2020 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 3,705 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
An investment in the Company’s common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the SEC on March 30, 2020, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our common stock. Except as set forth below, there have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2019. The Company’s business, operating results and financial condition could be adversely affected due to any of those risks. In addition:
We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth.
As our business strategies develop, we must add additional managerial, operational, financial and other personnel. Future growth will impose significant added responsibilities on members of management, including:
- identifying, recruiting, integrating, maintaining, and motivating additional personnel;
- managing our internal development efforts effectively, while complying with our contractual obligations to contractors and other third parties; and
- improving our operational, financial and management controls, reporting systems, and procedures.
Our future financial performance will depend, in part, on our ability to effectively manage any future growth, which might be impacted by the COVID-19 outbreak, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. This lack of long-term experience working together may adversely impact our senior management team’s ability to effectively manage our business and growth.
We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, we may not be able to advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop our business initiatives and, accordingly, may not achieve our research, development, and commercialization goals.
We face risks related to health epidemics and other outbreaks, which could significantly disrupt our operations.
Our business and operating results could be adversely impacted by the effects of epidemics, including but not limited to the current COVID-19 pandemic. We are closely monitoring the impact of the COVID-19 global outbreak, although there remains significant uncertainty related to the public health situation globally. Our results of operations could be adversely affected to the extent that such coronavirus or any other epidemic generally harms the global economy.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $9.1m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $13.4m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $2.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $3.9m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $6.9m | us-gaap:GrossProfit |
| Gross profit | 6 months2020-01-01 to 2020-06-30 | $9.4m | us-gaap:GrossProfit |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$3.2m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$5.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $228.9k | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $1.0m | us-gaap:InterestExpense |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$3.4m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$5.8m | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 61,743,697 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 57,616,266 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$1.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2020-06-30 | $336.2k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $2.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $3.0m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $7.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $7.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-06-30 | −$4.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001493152-20-015934. Last ingested by Listed: Nov 13, 2026, 16:33 ET. Listed shows no prices and gives no investment advice.